<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00031616</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000069205</org_study_id>
    <secondary_id>NB-1011-1001</secondary_id>
    <secondary_id>NCI-V01-1689</secondary_id>
    <nct_id>NCT00031616</nct_id>
  </id_info>
  <brief_title>NB1011 in Treating Patients With Metastatic or Recurrent Colorectal Cancer</brief_title>
  <official_title>A Phase I/II Study Of NB1011 Administered Intravenously Daily For 5 Days Every 4 Weeks In Fluoropyrimidine-Resistant Metastatic Or Relapsed Colorectal Cancers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NewBiotics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die.&#xD;
&#xD;
      PURPOSE: Phase I/II trial to study the effectiveness of NB1011 in treating patients who have&#xD;
      metastatic or recurrent colorectal cancer that has not responded to previous treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the maximum tolerated dose of NB1011 in patients with&#xD;
           fluoropyrimidine-resistant metastatic or recurrent colorectal cancer.&#xD;
&#xD;
        -  Determine the safety and toxic effects of this drug in these patients.&#xD;
&#xD;
        -  Determine the pharmacokinetics of this drug in these patients.&#xD;
&#xD;
        -  Determine the efficacy of this drug in these patients.&#xD;
&#xD;
      OUTLINE: This is a phase I dose-escalation study followed by a phase II study.&#xD;
&#xD;
        -  Phase I: Patients receive NB1011 IV over 1 hour on days 1-5. Treatment repeats every 28&#xD;
           days for up to 6 courses in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of NB1011 until the maximum tolerated dose&#xD;
      (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2 of 6&#xD;
      patients experience dose-limiting toxicity.&#xD;
&#xD;
        -  Phase II: Additional patients receive NB1011 at the MTD as in phase I. Patients are&#xD;
           followed at day 30 and then for 5 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A maximum of 25 patients will be accrued for the phase I portion of this&#xD;
      study. A total of 15-25 patients will be accrued for the phase II portion of this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>December 2001</start_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Colorectal Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>brivudine phosphoramidate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed metastatic or recurrent colorectal&#xD;
             adenocarcinoma that has progressed during or within 6 months of fluoropyrimidine-based&#xD;
             therapy&#xD;
&#xD;
          -  Prior treatment with irinotecan with or without fluorouracil&#xD;
&#xD;
          -  Evaluable or measurable disease&#xD;
&#xD;
               -  Uni-dimensionally measurable disease allowed provided CEA is at least 2 times the&#xD;
                  upper limit of normal&#xD;
&#xD;
          -  No meningeal or CNS metastases or carcinomatous meningitis&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Karnofsky 70-100%&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  At least 3 months&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC at least 3,000/mm^3&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin less than 1.5 mg/dL (regardless of liver metastases)&#xD;
&#xD;
          -  AST and ALT less than 1.5 times upper limit of normal (ULN) (3 times ULN if liver&#xD;
             metastases present)&#xD;
&#xD;
          -  PT and INR normal&#xD;
&#xD;
          -  PTT normal&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine less than 1.5 mg/dL OR&#xD;
&#xD;
          -  Creatinine clearance greater than 50 mL/min&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No known hypersensitivity to NB1011 or any excipient or vehicle in its formulation&#xD;
&#xD;
          -  No active or uncontrolled serious bacterial, viral, fungal, or parasitic infection&#xD;
&#xD;
          -  No prior or concurrent alcohol abuse or dependency&#xD;
&#xD;
          -  No other malignancy within the past 2 years except adequately treated basal cell or&#xD;
             squamous cell skin cancer or carcinoma in situ of the cervix&#xD;
&#xD;
          -  No concurrent medical or psychological condition that would preclude study&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Recovered from prior anticancer chemotherapy&#xD;
&#xD;
          -  No concurrent fluoropyrimidine-based or thymidylate synthase inhibitor agents&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  Recovered from prior anticancer radiotherapy&#xD;
&#xD;
          -  No concurrent radiotherapy except palliative radiotherapy (to control a fracture or&#xD;
             pain) provided index lesions are not involved&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Recovered from prior anticancer surgery&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  At least 30 days since prior investigational agents&#xD;
&#xD;
          -  No other concurrent anticancer therapy&#xD;
&#xD;
          -  No concurrent disulfiram&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark D. Pegram, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Jonsson Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>USC/Norris Comprehensive Cancer Center and Hospital</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jonsson Comprehensive Cancer Center, UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2004</verification_date>
  <study_first_submitted>March 8, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>December 17, 2013</last_update_submitted>
  <last_update_submitted_qc>December 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 18, 2013</last_update_posted>
  <keyword>stage IV colon cancer</keyword>
  <keyword>stage IV rectal cancer</keyword>
  <keyword>recurrent colon cancer</keyword>
  <keyword>recurrent rectal cancer</keyword>
  <keyword>adenocarcinoma of the colon</keyword>
  <keyword>adenocarcinoma of the rectum</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brivudine</mesh_term>
    <mesh_term>Phosphoramidic acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

